{"id":"https://openalex.org/W2062301656","doi":"https://doi.org/10.1038/clpt.2013.223","title":"Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan","display_name":"Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan","publication_year":2013,"publication_date":"2013-11-08","ids":{"openalex":"https://openalex.org/W2062301656","doi":"https://doi.org/10.1038/clpt.2013.223","mag":"2062301656","pmid":"https://pubmed.ncbi.nlm.nih.gov/24213186"},"language":"en","primary_location":{"id":"doi:10.1038/clpt.2013.223","doi":"https://doi.org/10.1038/clpt.2013.223","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2013.223","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"T Ueno","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I173865709","display_name":"Gifu Pharmaceutical University","ror":"https://ror.org/0372t5741","country_code":"JP","type":"education","lineage":["https://openalex.org/I173865709"]},{"id":"https://openalex.org/I91962293","display_name":"Pharmaceuticals and Medical Devices Agency","ror":"https://ror.org/03mpkb302","country_code":"JP","type":"government","lineage":["https://openalex.org/I91962293"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"T Ueno","raw_affiliation_strings":["1] Pharmaceuticals and Medical Devices Agency, Tokyo, Japan [2] Gifu Pharmaceutical University, Gifu, Japan","Gifu Pharmaceutical University, Gifu, Japan","Pharmaceuticals and Medical Devices Agency, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1] Pharmaceuticals and Medical Devices Agency, Tokyo, Japan [2] Gifu Pharmaceutical University, Gifu, Japan","institution_ids":["https://openalex.org/I173865709","https://openalex.org/I91962293"]},{"raw_affiliation_string":"Gifu Pharmaceutical University, Gifu, Japan","institution_ids":["https://openalex.org/I173865709"]},{"raw_affiliation_string":"Pharmaceuticals and Medical Devices Agency, Tokyo, Japan","institution_ids":["https://openalex.org/I91962293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113882654","display_name":"Yasuko Asahina","orcid":"https://orcid.org/0009-0005-2446-033X","observed_orcids":["https://orcid.org/0009-0005-2446-033X"]},"institutions":[{"id":"https://openalex.org/I91962293","display_name":"Pharmaceuticals and Medical Devices Agency","ror":"https://ror.org/03mpkb302","country_code":"JP","type":"government","lineage":["https://openalex.org/I91962293"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Y Asahina","raw_affiliation_strings":["Pharmaceuticals and Medical Devices Agency, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceuticals and Medical Devices Agency, Tokyo, Japan","institution_ids":["https://openalex.org/I91962293"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A Tanaka","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I91962293","display_name":"Pharmaceuticals and Medical Devices Agency","ror":"https://ror.org/03mpkb302","country_code":"JP","type":"government","lineage":["https://openalex.org/I91962293"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"A Tanaka","raw_affiliation_strings":["Pharmaceuticals and Medical Devices Agency, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceuticals and Medical Devices Agency, Tokyo, Japan","institution_ids":["https://openalex.org/I91962293"]}]},{"author_position":"middle","author":{"id":null,"display_name":"H Yamada","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I173865709","display_name":"Gifu Pharmaceutical University","ror":"https://ror.org/0372t5741","country_code":"JP","type":"education","lineage":["https://openalex.org/I173865709"]},{"id":"https://openalex.org/I91962293","display_name":"Pharmaceuticals and Medical Devices Agency","ror":"https://ror.org/03mpkb302","country_code":"JP","type":"government","lineage":["https://openalex.org/I91962293"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"H Yamada","raw_affiliation_strings":["1] Pharmaceuticals and Medical Devices Agency, Tokyo, Japan [2] Gifu Pharmaceutical University, Gifu, Japan","Gifu Pharmaceutical University, Gifu, Japan","Pharmaceuticals and Medical Devices Agency, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1] Pharmaceuticals and Medical Devices Agency, Tokyo, Japan [2] Gifu Pharmaceutical University, Gifu, Japan","institution_ids":["https://openalex.org/I173865709","https://openalex.org/I91962293"]},{"raw_affiliation_string":"Gifu Pharmaceutical University, Gifu, Japan","institution_ids":["https://openalex.org/I173865709"]},{"raw_affiliation_string":"Pharmaceuticals and Medical Devices Agency, Tokyo, Japan","institution_ids":["https://openalex.org/I91962293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055962201","display_name":"Mitsuhiro Nakamura","orcid":"https://orcid.org/0000-0002-5062-5522","observed_orcids":["https://orcid.org/0000-0002-5062-5522"]},"institutions":[{"id":"https://openalex.org/I173865709","display_name":"Gifu Pharmaceutical University","ror":"https://ror.org/0372t5741","country_code":"JP","type":"education","lineage":["https://openalex.org/I173865709"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"M Nakamura","raw_affiliation_strings":["Gifu Pharmaceutical University, Gifu, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gifu Pharmaceutical University, Gifu, Japan","institution_ids":["https://openalex.org/I173865709"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5031727238","display_name":"Yoshiaki Uyama","orcid":"https://orcid.org/0000-0002-0430-9887","observed_orcids":["https://orcid.org/0000-0002-0430-9887"]},"institutions":[{"id":"https://openalex.org/I159385669","display_name":"Chiba University","ror":"https://ror.org/01hjzeq58","country_code":"JP","type":"education","lineage":["https://openalex.org/I159385669"]},{"id":"https://openalex.org/I91962293","display_name":"Pharmaceuticals and Medical Devices Agency","ror":"https://ror.org/03mpkb302","country_code":"JP","type":"government","lineage":["https://openalex.org/I91962293"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Y Uyama","raw_affiliation_strings":["1] Pharmaceuticals and Medical Devices Agency, Tokyo, Japan [2] Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan","Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan","Pharmaceuticals and Medical Devices Agency, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1] Pharmaceuticals and Medical Devices Agency, Tokyo, Japan [2] Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan","institution_ids":["https://openalex.org/I159385669","https://openalex.org/I91962293"]},{"raw_affiliation_string":"Department of Regulatory Science of Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan","institution_ids":["https://openalex.org/I159385669"]},{"raw_affiliation_string":"Pharmaceuticals and Medical Devices Agency, Tokyo, Japan","institution_ids":["https://openalex.org/I91962293"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5031727238"],"corresponding_institution_ids":["https://openalex.org/I159385669","https://openalex.org/I91962293"],"apc_list":{"value":4410,"currency":"USD","value_usd":4410},"apc_paid":null,"fwci":8.4783,"has_fulltext":false,"cited_by_count":71,"citation_normalized_percentile":{"value":0.97056541,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"95","issue":"5","first_page":"533","last_page":"541"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.8481000065803528,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.8481000065803528,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.057100001722574234,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.05400000140070915,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/drug-lag","display_name":"drug lag","score":0.9359999895095825},{"id":"https://openalex.org/keywords/new-drug-application","display_name":"new drug applications","score":0.6190000176429749},{"id":"https://openalex.org/keywords/regulatory-submissions","display_name":"regulatory submissions","score":0.765999972820282},{"id":"https://openalex.org/keywords/global-clinical-trials","display_name":"global clinical trials","score":0.8690000176429749},{"id":"https://openalex.org/keywords/clinical-development-strategy","display_name":"clinical development strategy","score":0.8809999823570251},{"id":"https://openalex.org/keywords/drug-development-time","display_name":"drug development time","score":0.46000000834465027},{"id":"https://openalex.org/keywords/sample-size","display_name":"sample size","score":0.4320000112056732}],"concepts":[{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.8003467321395874},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.7006036043167114},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6720635890960693},{"id":"https://openalex.org/C63433958","wikidata":"https://www.wikidata.org/wiki/Q1774688","display_name":"Clinical pharmacology","level":2,"score":0.6385295987129211},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5345275402069092},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4383728504180908},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42182764410972595},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3838939070701599},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23573771119117737},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.16078096628189087}],"mesh":[{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D004335","descriptor_name":"Drug and Narcotic Control","qualifier_ui":"Q000331","qualifier_name":"legislation & jurisprudence","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007564","descriptor_name":"Japan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":"Q000331","qualifier_name":"legislation & jurisprudence","is_major_topic":true},{"descriptor_ui":"D018401","descriptor_name":"Sample Size","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1038/clpt.2013.223","doi":"https://doi.org/10.1038/clpt.2013.223","is_oa":false,"landing_page_url":"https://doi.org/10.1038/clpt.2013.223","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:24213186","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24213186","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:irdb.nii.ac.jp:07563:0007339931","doi":null,"is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jcyt.2025.02.010","pdf_url":null,"source":{"id":"https://openalex.org/S7407056385","display_name":"Institutional Repositories DataBase (IRDB)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I184597095","host_organization_name":"National Institute of Informatics","host_organization_lineage":["https://openalex.org/I184597095"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan","raw_type":"journal article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8048999905586243,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":12,"referenced_works":["https://openalex.org/W1759608414","https://openalex.org/W1972618934","https://openalex.org/W1974571165","https://openalex.org/W1995604988","https://openalex.org/W2009852994","https://openalex.org/W2023970099","https://openalex.org/W2046904904","https://openalex.org/W2063500683","https://openalex.org/W2094844853","https://openalex.org/W2125416781","https://openalex.org/W2312467916","https://openalex.org/W2915081203"],"related_works":["https://openalex.org/W4393928408","https://openalex.org/W3186763341","https://openalex.org/W2010072448","https://openalex.org/W2716977314","https://openalex.org/W7207562588","https://openalex.org/W1986881091","https://openalex.org/W3083818708","https://openalex.org/W4212850889","https://openalex.org/W2081666142","https://openalex.org/W4206288528"],"abstract_inverted_index":{"Although":[0,78],"the":[1,28,36,45,52,62,75,96,105,113,118],"number":[2],"of":[3,54,69,102,117,128],"global":[4],"clinical":[5,56,70,106],"trials":[6,71],"(GCTs)":[7],"conducted":[8,73],"in":[9,26,30,44,98,104,139],"multiple":[10],"countries":[11],"including":[12],"Japan":[13],"has":[14],"increased":[15],"recently,":[16],"it":[17],"is":[18,91,109],"not":[19],"clear":[20],"how":[21],"much":[22],"these":[23],"GCTs":[24,103],"help":[25],"reducing":[27],"lag":[29],"drug":[31,41,80,133],"development":[32,57,63,81,107,134],"(LDD:":[33],"difference":[34],"between":[35],"submission":[37],"dates":[38],"for":[39,74],"new":[40],"applications":[42],"(NDAs)":[43],"United":[46],"States":[47],"and":[48],"Japan).":[49],"We":[50],"examined":[51],"effects":[53],"various":[55,79],"strategies":[58,82],"on":[59,66,87],"LDD":[60,97],"because":[61],"period":[64],"depends":[65],"what":[67],"types":[68],"were":[72],"Japanese":[76,119,144],"NDA.":[77],"are":[83],"available,":[84],"deciding":[85],"early":[86],"an":[88],"appropriate":[89],"strategy":[90,108],"a":[92],"key":[93],"to":[94,131,143],"minimizing":[95],"Japan.":[99],"The":[100],"inclusion":[101],"also":[110,136],"important;":[111],"simultaneously,":[112],"smaller":[114],"sample":[115],"size":[116],"population":[120],"should":[121],"be":[122,137],"taken":[123],"into":[124],"consideration.":[125],"Furthermore,":[126],"reinforcement":[127],"Japan's":[129],"capability":[130],"lead":[132],"may":[135],"important":[138],"providing":[140],"innovative":[141],"drugs":[142],"patients":[145],"without":[146],"any":[147],"significant":[148],"LDD.":[149]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":11},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":10},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}